Carbamazepine (All indications)

Spina bifida

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9664
R34408		 Jentink (Carbamazepine), 2010 Spina bifida 1st trimester case control unexposed (general population or NOS) Adjustment: Yes 2.60 [1.20;5.30] 8/-   -/- - -
ref
S9666
R34414		 Källén (Carbamazepine), 1994 Spina bifida during pregnancy (anytime or not specified) excluded nested case control unexposed, sick Adjustment: No Matched 39.00 [0.53;2883.82] C
excluded (exposition period) 		2/3   0/6 2 3
ref
S9767
R34921		 Czeizel (Carbamazepine) (Mixed indications), 1992 Spina bifida throughout pregnancy case control unexposed, sick Adjustment: No Controls: epilepsy indication 1.20 [0.07;19.63] C 2/7   1/4 3 7
ref
Total 2 studies 2.47 [1.21;5.06] 3 7
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Jentink (Carbamazepine), 2010Jentink, 2010 1 2.60[1.20; 5.30]--93%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Czeizel (Carbamazepine) (Mixed indications), 1992Czeizel, 1992 2 1.20[0.07; 19.63]377%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 2.47[1.21; 5.06]370.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine; 2: Carbamazepine) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 2.47[1.21; 5.06]370%NAJentink (Carbamazepine), 2010 Czeizel (Carbamazepine) (Mixed indications), 1992 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.60[1.24; 5.46]-- -NAJentink (Carbamazepine), 2010 1 unexposed, sickunexposed, sick 1.20[0.07; 19.63]37 -NACzeizel (Carbamazepine) (Mixed indications), 1992 1 Tags Adjustment   - No  - No 1.20[0.07; 19.63]37 -NACzeizel (Carbamazepine) (Mixed indications), 1992 1   - Yes  - Yes 2.60[1.24; 5.46]-- -NAJentink (Carbamazepine), 2010 1 Controls   - epilepsy indication  - epilepsy indication 1.20[0.07; 19.63]37 -NACzeizel (Carbamazepine) (Mixed indications), 1992 1 All studiesAll studies 2.47[1.21; 5.06]370%NAJentink (Carbamazepine), 2010 Czeizel (Carbamazepine) (Mixed indications), 1992 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.83[1.40; 5.71]6175230%NABlotière (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 Jentink (Carbamazepine), 2010 Van der Pol (Carbamazepine) (Controls unexposed, disease free), 1991 3 unexposed, sick controlsunexposed, sick controls 0.82[0.22; 3.07]91,8910%NAVeiby (Carbamazepine) (Controls unexposed, sick) (Mixed indications), 2014 Charlton (Carbamazepine) (Controls unexposed, sick), 2011 Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 Artama (Carbamazepine), 2005 Czeizel (Carbamazepine) (Mixed indications), 1992 Van der Pol (Carbamazepine) (Controls unexposed, sick), 1991 6 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.91[0.27; 13.55]21,5080%NABlotière (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Charlton (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 30.510.01.0